Biohaven Ltd(BHVN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 7:21 PM ET (Korea 10/28 08:21)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -4.65 | Insider Own | 14.89% | Shs Outstand | 151.0M | Perf Week | 29.47% |
| Market Cap | 2.31B | Forward P/E | - | EPS next Y | -3.74% | Insider Trans | - | Shs Float | 128.6M | Perf Month | 15.22% |
| Enterprise Value | 2.34B | PEG | - | EPS next Q | -0.78 | Inst Own | 91.23% | Short Float | 13.92% | Perf Quarter | 13.85% |
| Income | -0.59B | P/S | - | EPS this Y | 65.9% | Inst Trans | -4.99% | Short Ratio | 5.79 | Perf Half Y | 59.11% |
| Sales | 0.00B | P/B | 188.93 | EPS next 5Y | 33.11% | ROA | -127.41% | Short Interest | 17.90M | Perf YTD | 35.43% |
| Book/sh | 0.08 | P/C | 8.62 | EPS past 3/5Y | 6.37% -30.08% | ROE | -799.46% | 52W High | -17.64% ($18.57) | Perf Year | -12.08% |
| Cash/sh | 1.77 | P/FCF | - | Sales past 3/5Y | - | ROIC | -192.67% | 52W Low | 104.41% ($7.48) | Perf 3Y | -43.03% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 39.33% | Gross Margin | - | Volatility(W/M) | 9.17% 6.48% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.1 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.73 | EPS Q/Q | 52.91% | Profit Margin | - | RSI (14) | 64.31 | Recom | 1.71 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.73 | Sales Q/Q | - | SMA20 | 22.37% ($12.49) | Beta | 3.19 | Target Price | $25.17 |
| Payout | - | Debt/Eq | 24.31 | Earnings | 2026/8/10 | SMA50 | 13.27% ($13.5) | Rel Volume | 0.79 | Prev Close | $14.45 |
| Employees | 274 | LT Debt/Eq | 23.93 | EPS/Sales Surpr. | -19.58% - | SMA200 | 25.72% ($12.16) | Avg Volume(3M) | 3.09M | Price | $15.29 |
| IPO | 2017/5/4 | Option/Short | Yes/Yes | Trades | 11682 | Volume | 2,430,708 | Change | 5.81% |
🧬 This is a clinical-stage biotech company developing therapeutics across multiple areas, including neuroscience and immunology. It is developing a diverse range of candidate compounds in areas such as neurological disorders, immunology, and rare diseases, and maintains a broad pipeline and a differentiated novel drug platform. The company has established itself as a clinical-stage biotech with a wide-ranging pipeline across multiple therapeutic areas.
Over the past 1 year, roughly in the middle
18% below its 1-year high.
Traded less than usual. That is 79% of its average volume.
BHVN has weak earning power
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +65.9% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Long-term returns are roughly flat
Bought 3 years ago, your return today would be -43.0%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 91.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #87 of 594 in the industry
Based on market cap of $2B.
FAQ
What kind of company is BHVN?
BHVN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BHVN?
The market cap of BHVN is approximately $2.3B, ranking 1,948 within its sector.
What is the 52-week high and low for BHVN?
BHVN has recorded a 52-week high of $18.57 and a low of $7.48.
